Physician profile
Michael Robert Cohen
NPI 1316057821
$13,825.10
in general payments reported to CMS, 2019-2025
56 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 95% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,915 · 2020: $1,038 · 2021: $1,501 · 2022: $2,516 · 2023: $2,279 · 2024: $2,278 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,855.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,864.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,463.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,302.18 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $1,045.41 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,007.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $513.31 | 2019-2025 | Ofev, Jardiance, Synjardy |
| Astellas Pharma US INC | $477.97 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $448.77 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $402.68 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $384.90 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $369.74 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $332.72 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $312.06 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.45 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $274.87 | 2022-2025 | Rexulti |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.